Approximately one‐half of individuals with cancer face personal economic burdens
associated with the disease and its treatment, a problem known as financial toxicity (FT). FT …

Financial toxicity describes the financial burden and distress that can arise for patients, and
their family members, as a result of cancer treatment. It includes direct out-of-pocket costs for …

Purpose Financial toxicity related to cancer diagnosis and treatment is a common issue in
developed countries. We seek to systematically summarize the extent of the issue in very …

Background Young adult (YA) cancer survivors are at risk for financial toxicity during and
after cancer treatment. Financial toxicity has been associated with medical‐related cost …

Background Financial toxicity is commonly reported by cancer patients, but few studies have
assessed caregiver perceptions. We aimed to validate the modified Comprehensive Score …

Background: Cancer-related financial hardship is associated with poor care outcomes and
reduced quality of life for patients and families. Scalable intervention development to …

Objectives Financial toxicity is recognized as an important adverse effect of cancer treatment
that may decrease patients' health-related quality of life (HRQOL). We aim to perform a …

Paclitaxel (PTX) is a chemotherapeutic agent that belongs to the taxane family and which
was approved to treat various kinds of cancers including breast cancer, ovarian cancer …

Simple Summary For cancer patients, many different reasons can cause financial burdens
and economic threads. Sociodemographic factors, rural/remote location and income are …

The complexity of the cellular and acellular players within the tumor microenvironment
(TME) allows for significant variation in TME constitution and role in anticancer treatment …